SI
CRL icon

Sapience Investments’s Charles River Laboratories CRL Stock Holding History

Sapience Investments’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,353
Closed -$463K – 87
2024
Q3 		$463K Hold
2,353
– – 0.23% 85
2024
Q2 		$486K Hold
2,353
– – 0.25% 81
2024
Q1 		$638K Hold
2,353
– – 0.21% 73
2023
Q4 		$556K Hold
2,353
– – 0.13% 75
2023
Q3 		$461K Hold
2,353
– – 0.11% 72
2023
Q2 		$495K Sell
2,353
-465
-17% -$92.5K 0.11% 70
2023
Q1 		$569K Buy
2,818
+463
+20% +$105K 0.13% 68
2022
Q4 		$513K Buy
+2,355
New +$514K 0.11% 77

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Sapience Investments's CRL Position: Q4 2024 in Review

Sapience Investments sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 2,353 shares — an estimated $463K sold.

Sapience Investments first reported a position in CRL in Q4 2022 and held it in 8 quarters. The position peaked at $638K in Q1 2024. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Sapience Investments reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Sapience Investments sold 2,353 Charles River Laboratories shares in Q4 2024, an estimated $463K.
  • Sapience Investments first reported a position in Charles River Laboratories in Q4 2022 and held it in 8 quarters.
  • Sapience Investments's Charles River Laboratories position peaked at $638K in Q1 2024.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Sapience Investments's 13F filing for Q4 2024, filed 14 Feb 2025.